Zenas BioPharma (ZBIO) Total Current Liabilities (2023 - 2026)

Zenas BioPharma's Total Current Liabilities history runs 4 years deep, the most recent figure standing at $61.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 24.48% year-over-year to $61.2 million; the TTM figure through Mar 2026 stood at $61.2 million (up 24.48% YoY), while the FY2025 annual figure was $62.6 million, up 9.35% from the prior year.
• Total Current Liabilities was $61.2 million for Q1 2026 at Zenas BioPharma, down from $62.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $62.6 million in Q4 2025 to a low of $23.3 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $50.4 million across 4 years, with a median of $52.8 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 146.33% in 2024, then advanced 9.35% in 2025.
• A 4-year view of Total Current Liabilities shows it stood at $23.3 million in 2023, then soared by 146.33% to $57.3 million in 2024, then grew by 9.35% to $62.6 million in 2025, then fell by 2.38% to $61.2 million in 2026.
• The last three Total Current Liabilities figures came in at $61.2 million (Q1 2026), $62.6 million (Q4 2025), and $52.4 million (Q3 2025), per Business Quant data.